Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter to Distribute Strand's NGS Analysis Software in Europe

NEW YORK (GenomeWeb) – Tataa Biocenter and Strand Life Sciences have formed a strategic partnership, under which Tataa will distribute Strand's next-generation sequence data analysis software — Strand NGS — in Europe and also provide support for customers in that market.

Gӧteborg, Sweden-based Tataa also said that it will use Strand NGS, an integrated platform that offers tools for analyzing, managing, and visualizing NGS data, in its NGS training courses. Features of the platform include workflows for handling and analyzing DNA-seq, RNA-seq, small RNA-seq, ChIP-seq, and methyl-seq data; a browser tool for visualizing SNPs, insertions and deletions, large structural rearrangements, and more; and annotations for several standard organisms culled from various sources.

The partnership with Bangalore, India-based Strand enables Tataa to address customers' demands for comprehensive solutions that support their NGS workflows, Mikael Kubista, Tataa's president, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.